Afami-cel 为罕见的肉瘤亚型提供了新的治疗方案

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-04-18 DOI:10.1038/s41571-024-00894-y

Peter Sidaway

引用次数: 0

摘要

转移性或无法切除的滑膜肉瘤或肌圆细胞脂肪肉瘤（占所有软组织肉瘤的5-10%）患者的长期生存率通常很有限，尤其是在接受一线治疗后疾病复发的情况下。现在，测试afamitresgene autoleucel（afami-cel）（一种用亲和力增强的MAGE-A4特异性T细胞受体转导的CD4+和CD8+T细胞产品）的II期SPEARHEAD-1试验数据为该疗法的安全性和疗效提供了令人鼓舞的证据。未观察到完全应答。滑膜肉瘤（44 例）和类肉圆形细胞脂肪肉瘤（8 例）患者的 ORR 分别为 39% 和 25%。这些患者的中位反应持续时间分别为11.6个月和4.2个月。整个组群的中位无进展生存期为3.7个月，中位总生存期为16.9个月。不需要桥接疗法、MAGE A4表达H评分≥200分以及靶病灶基线总和为100毫米都与ORR的提高有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Afami-cel provides a novel treatment option for rare sarcoma subtypes

查看原文本刊更多论文

Afami-cel provides a novel treatment option for rare sarcoma subtypes

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.